Clinical application of CT-guided percutaneous targeted argon-helium cryoablation for soft tissue sarcoma.
- Author:
Qian SONG
1
;
Ying ZHAN
;
Lu-jia LI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Argon; Cryosurgery; methods; Extremities; Female; Helium; Humans; Liver Neoplasms; surgery; Lung Neoplasms; surgery; Male; Middle Aged; Radiography, Interventional; Sarcoma; surgery; Tomography, X-Ray Computed; Treatment Outcome
- From: Journal of Southern Medical University 2006;26(2):229-230
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the clinical efficacy of percutaneous targeted argon-helium cryoablation for soft tissue sarcoma and analyze the changes in CT findings and side effects in relation to the treatment.
METHODSThirty-two patients with soft tissue sarcoma were treated with CT-guided argon-helium cryoablation.
RESULTSThree months after the treatment, 52 tumors showed obvious reduction in size with a total complete and partial remission rate of 73.1%. Postoperative CT scanning displayed low-density local necrosis in the tumors after cryotherapy, and consolidation of the lesions was observed at 3 months and lesion disappearance at 1 year after the therapy. The complications included pneumothorax, coughing, hemoptysis, fever, and slight elevation of aminotransferase.
CONCLUSIONCT-guided percutaneous targeted argon-helium cryoablation is safe and effective for lung cancer with minimal invasions.
